Glycated albumin induces lipid infiltration in mice aorta independently of DM and RAS local modulation by inducing lipid peroxidation and inflammation

Imagem de Miniatura
Arquivos
art_GOMES_Glycated_albumin_induces_lipid_infiltration_in_mice_aorta_2016.PDF (1.1 MB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
WOODS, Tom
BRIMBLE, Margaret Anne
Citação
JOURNAL OF DIABETES AND ITS COMPLICATIONS, v.30, n.8, p.1614-1621, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims: Advanced glycated albumin (AGE-albumin) adversely impairs macrophage lipid homeostasis in vitro, which may be prevented by angiotensin receptor blockers. In vivo studies are inconclusive whether AGE-albumin itself plays important role in early-stage atherogenesis. We aimed at investigating how AGE-albumin by itself drives atherosclerosis development in dyslipidemic non-diabetic mice and if its effects are due to the activation of renin-angiotensin system in the arterial wall and the expression of genes and proteins involved in lipid flux. Methods and results: Murine albumin glycation was induced by incubation with 10 mM glycolaldehyde and C-albumin with PBS alone. Twelve-week-old-male apoE knockout mice were submitted to a daily IP injection of control (C) or AGE-albumin (2 mg/mL) during 30 days with or without losartan (LOS: 100 mg/L; C + LOS and AGE + LOS). Aortic arch was removed, and gene expression was determined by RT-PCR and protein content by immunofluorescence. Plasma lipid and glucose levels were similar among groups. Systolic blood pressure was similarly reduced in both groups treated with LOS. In comparison to C-albumin, aortic lipid infiltration was 5.3 times increased by AGE-albumin, which was avoided by LOS. LOS prevented the enhancement induced by AGE-albumin in Ager, Tnf and Cybb mRNA levels but did not reduce Olrl. Nfkb and Agt mRNA levels were unchanged by AGE-albumin. LOS similarly reduced Agtri a mRNA level in both C and AGE-albumin groups. In AGE-albumin-treated mice, immunofluorescence for carboxymethyl-lysine, 4-hydroxynonenal and RAGE was respectively, 4.8, 2.6 and 1.7 times enhanced in comparison to C-albumin. These increases were all avoided by LOS. Conclusions: AGE-albumin evokes a pre-stage of atherogenesis in dyslipidemic mice independently of the presence of diabetes mellitus or modulation in the RAS in part by the induction of lipid peroxidation and inflammation.
Palavras-chave
Advanced glycation, Glycated albumin, Atherosclerosis, Losartan, Oxidative stress, Inflammation
URI
https://observatorio.fm.usp.br/handle/OPI/19961
Referências
  1. Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792
  2. Bierhaus A, 1998, CARDIOVASC RES, V37, P586, DOI 10.1016/S0008-6363(97)00233-2
  3. Bro S, 2008, ATHEROSCLEROSIS, V201, P274, DOI 10.1016/j.atherosclerosis.2008.01.015
  4. Bustin SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755
  5. Calkin AC, 2008, DIABETOLOGIA, V51, P1731, DOI 10.1007/s00125-008-1060-6
  6. Castilho G, 2012, INT J BIOCHEM CELL B, V44, P1078, DOI 10.1016/j.biocel.2012.03.016
  7. Costal F, 2013, DIABETES-METAB RES, V29, P296, DOI 10.1002/dmrr.2390
  8. Coughlan MT, 2011, DIABETES, V60, P2523, DOI 10.2337/db10-1033
  9. Daugherty A, 2004, CIRCULATION, V110, P3849, DOI 10.1161/01.CIR.0000150540.54220.C4
  10. Daugherty A, 2008, FUTURE LIPIDOL, V3, P625, DOI 10.2217/17460875.3.6.625
  11. Del Turco S, 2012, BIOFACTORS, V38, P266, DOI 10.1002/biof.1018
  12. de Souza Pinto R., 2012, LIPIDS, V47, P443
  13. Douglas G, 2012, CARDIOVASC RES, V94, P20, DOI 10.1093/cvr/cvs026
  14. Drummond GR, 2014, TRENDS ENDOCRIN MET, V25, P452, DOI 10.1016/j.tem.2014.06.012
  15. Dunn S, 2008, BIOCHEM J, V409, P349, DOI 10.1042/BJ20071196
  16. Fukami K, 2004, KIDNEY INT, V66, P2137, DOI 10.1111/j.1523-1755.2004.66004.x
  17. Furusyo N, 2013, INT J CARDIOL, V167, P2066, DOI 10.1016/j.ijcard.2012.05.045
  18. Goh SY, 2008, J CLIN ENDOCR METAB, V93, P1143, DOI 10.1210/jc.2007-1817
  19. Goodwin M, 2013, J GASTROEN HEPATOL, V28, P369, DOI 10.1111/jgh.12042
  20. Hanssen NMJ, 2015, DIABETES, V64, P257, DOI 10.2337/db13-1864
  21. Hayashi K, 2012, J ATHEROSCLER THROMB, V19, P736
  22. Iborra RT, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-172
  23. Ihara Y, 2007, J MOL CELL CARDIOL, V43, P455, DOI 10.1016/j.yjmce.2007.07.044
  24. Kang MK, 2016, ARCH PHARM RES, V39, P565, DOI 10.1007/s12272-016-0728-6
  25. Koka V, 2006, CIRCULATION, V113, P1353, DOI 10.1161/CIRCULATIONAHA.105.575589
  26. Kubista Mikael, 2006, Molecular Aspects of Medicine, V27, P95, DOI 10.1016/j.mam.2005.12.007
  27. Low H, 2012, DIABETOLOGIA, V55, P2513, DOI 10.1007/s00125-012-2570-9
  28. Ludovico-Martins H, 2009, TRANSPL P, V41, P862, DOI 10.1016/j.transproceed.2009.01.073
  29. Machado JT, 2014, ATHEROSCLEROSIS, V237, P343, DOI 10.1016/j.atherosclerosis.2014.09.020
  30. Machado-Lima A, 2015, J CELL PHYSIOL, V230, P1250, DOI 10.1002/jcp.24860
  31. Machado-Lima A, 2013, DIABETES-METAB RES, V29, P66, DOI 10.1002/dmrr.2362
  32. Matsuki K, 2009, ATHEROSCLEROSIS, V206, P434, DOI 10.1016/j.atherosclerosis.2009.03.003
  33. Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006
  34. Nowotny K, 2015, BIOMOLECULES, V5, P194, DOI 10.3390/biom5010194
  35. Okuda LS, 2012, BBA-MOL CELL BIOL L, V1821, P1485, DOI 10.1016/j.bbalip.2012.08.011
  36. PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4
  37. PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P571
  38. Potter DD, 1998, CIRCULATION, V98, P800
  39. Rabbani N, 2014, BIOCHEM SOC T, V42, P511, DOI 10.1042/BST20140019
  40. Rabbani N, 2011, DIABETES, V60, P1973, DOI 10.2337/db11-0085
  41. Schupp N, 2005, ANN NY ACAD SCI, V1043, P685, DOI 10.1196/annals.1333.079
  42. Shiu SWM, 2012, J ATHEROSCLER THROMB, V19, P1083
  43. Soro-Paavonen A, 2008, DIABETES, V57, P2461, DOI 10.2337/db07-1808
  44. Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200
  45. Unoki H, 2007, DIABETES RES CLIN PR, V76, P236, DOI 10.1016/j.diabres.2006.09.016
  46. Uribarri J, 2011, DIABETES CARE, V34, P1610, DOI 10.2337/dc11-0091
  47. Wang Z, 2015, CELL BIOSCI, V5, DOI 10.1186/2045-3701-5-3
  48. Wassmann S, 2004, CIRCULATION, V110, P3062, DOI 10.1161/01.CIR.000137970.47771.AF
  49. Woods TM, 2013, AMINO ACIDS, V45, P319, DOI 10.1007/s00726-013-1498-9

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/10
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - ODS/03